Free tool
FAERS Monitor: Flector
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021234 or its brand name (Flector, Diclofenac Epolamine). Reports on generic versions are filed under their own applications.
Reports
4,227
Serious
1,478
35% of reports
Hospitalization
639
Death reported
116
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective648
- pain274
- drug hypersensitivity235
- nausea220
- off label use192
- headache176
- dizziness162
- rash156
- diarrhoea141
- malaise141
- fatigue140
- pruritus132
- fall129
- dyspnoea120
- pain in extremity111
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 35 |
| 2009 | 43 |
| 2010 | 590 |
| 2011 | 164 |
| 2012 | 584 |
| 2013 | 260 |
| 2014 | 198 |
| 2015 | 224 |
| 2016 | 276 |
| 2017 | 231 |
| 2018 | 309 |
| 2019 | 379 |
| 2020 | 315 |
| 2021 | 204 |
| 2022 | 125 |
| 2023 | 85 |
| 2024 | 59 |
| 2025 | 98 |
| 2026 | 40 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,932 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug hypersensitivitySignal | 235 | 6.0 | 5.3 | 993 |
| drug ineffectiveSignal | 648 | 2.4 | 2.3 | 590 |
| painSignal | 274 | 2.2 | 2.0 | 188 |
| fall | 129 | 1.9 | 1.6 | 58 |
| pain in extremity | 111 | 1.9 | 1.6 | 45 |
| rash | 156 | 1.8 | 1.5 | 54 |
| pruritus | 132 | 1.7 | 1.4 | 39 |
| dizziness | 162 | 1.6 | 1.4 | 38 |
| malaise | 141 | 1.6 | 1.4 | 32 |
| headache | 176 | 1.4 | 1.2 | 20 |
| nausea | 220 | 1.4 | 1.2 | 24 |
| off label use | 192 | 1.1 | 1.0 | 1 |
| diarrhoea | 141 | 1.1 | 0.9 | 1 |
| dyspnoea | 120 | 1.1 | 0.9 | 0 |
| fatigue | 140 | 0.9 | 0.8 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.